ACRO Biomedical Co Ltd
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally. It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. wa… Read more
Market Cap & Net Worth: ACRO Biomedical Co Ltd (ACBM)
ACRO Biomedical Co Ltd (PINK:ACBM) has a market capitalization of $60.04K ($60.04K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #43176 globally and #13849 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACRO Biomedical Co Ltd's stock price $0.00 by its total outstanding shares 60042000 (60.04 Million).
ACRO Biomedical Co Ltd Market Cap History: 2018 to 2025
ACRO Biomedical Co Ltd's market capitalization history from 2018 to 2025. Data shows change from $231.16 Million to $60.04K (-67.38% CAGR).
ACRO Biomedical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACRO Biomedical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.57x
ACRO Biomedical Co Ltd's market cap is 9.57 times its annual revenue
0.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $231.16 Million | $8.01 Million | $419.66K | 28.84x | 550.83x |
| 2019 | $218.55 Million | $193.54K | -$371.60K | 1129.26x | N/A |
| 2020 | $174.12 Million | $687.96K | -$117.45K | 253.10x | N/A |
| 2021 | $279.20 Million | $1.20 Million | -$7.70 Million | 233.15x | N/A |
| 2022 | $270.19 Million | $658.50K | -$15.87 Million | 410.31x | N/A |
| 2023 | $6.30 Million | $658.50K | -$15.87 Million | 9.57x | N/A |
Competitor Companies of ACBM by Market Capitalization
Companies near ACRO Biomedical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to ACRO Biomedical Co Ltd by market ranking:
- CLUS (PINK:CLUS): Ranked #1968 globally with a market cap of $8.00 Billion USD.
- Cartesian Growth Corporation II Warrant (NASDAQ:RENEW): Ranked #8546 globally with a market cap of $736.93 Million USD.
- Nh Special Purpose Acquisition 14 Co. Ltd (KQ:319400): Ranked #8994 globally with a market cap of $660.01 Million USD ( ₩966.39 Billion KRW).
- EQV Ventures Acquisition Corp. II (NYSE:EVAC): Ranked #10613 globally with a market cap of $465.51 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1968 | CLUS | PINK:CLUS | $8.00 Billion | $200.00 |
| #8546 | Cartesian Growth Corporation II Warrant | NASDAQ:RENEW | $736.93 Million | $138.87 |
| #8994 | Nh Special Purpose Acquisition 14 Co. Ltd | KQ:319400 | $660.01 Million | ₩30450.00 |
| #10613 | EQV Ventures Acquisition Corp. II | NYSE:EVAC | $465.51 Million | $10.07 |
ACRO Biomedical Co Ltd Historical Marketcap From 2018 to 2025
Between 2018 and today, ACRO Biomedical Co Ltd's market cap moved from $231.16 Million to $ 60.04K, with a yearly change of -67.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $60.04K | 0.00% |
| 2024 | $60.04K | -99.05% |
| 2023 | $6.30 Million | -97.67% |
| 2022 | $270.19 Million | -3.23% |
| 2021 | $279.20 Million | +60.34% |
| 2020 | $174.12 Million | -20.33% |
| 2019 | $218.55 Million | -5.45% |
| 2018 | $231.16 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ACRO Biomedical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.04K USD |
| MoneyControl | $60.04K USD |
| MarketWatch | $60.04K USD |
| marketcap.company | $60.04K USD |
| Reuters | $60.04K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.